Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE4
552 participants
INTERVENTIONAL
2018-04-18
2025-04-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan
NCT02208427
Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)
NCT01398618
Risk of SDRs Under 3HP and 1HP Regimen for LTBI
NCT04094012
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
NCT03474029
Clinical Analysis of Safety in Latent Tuberculosis Infection Prophylaxis Treatment
NCT04655794
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
3 months of weekly rifapentine plus isoniazid
3 months of weekly rifapentine plus isoniazid
Rifapentine and Isoniazid for 3 months
tuberculosis preventive therapy (TPT) with 3 months of weekly rifapentine plus isoniazid (3HP)
9 months of daily isoniazid
9 months of daily isoniazid
Isoniazid (INH) daily for 9 months
tuberculosis preventive therapy (TPT) with 9 months of daily isoniazid (9H)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rifapentine and Isoniazid for 3 months
tuberculosis preventive therapy (TPT) with 3 months of weekly rifapentine plus isoniazid (3HP)
Isoniazid (INH) daily for 9 months
tuberculosis preventive therapy (TPT) with 9 months of daily isoniazid (9H)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* poorly controlled DM (pDM), defined as HbA1c ≥9% within the preceding year
Exclusion Criteria
* immunocompromise (use of immunosuppressors
* current pregnancy
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taichung Veterans General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
I-Te Lee
Role: PRINCIPAL_INVESTIGATOR
Taichung Veterans General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Taichung Veterans General Hospital
Taichung, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TCVGH-CE18090B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.